Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Faculty Members have conducted research related to the Regorafenib Versus Cetuximab Plus Irinotecan in Third-Line Metastatic Colorectal Cancer in Iran: A Model-Based Cost-Utility Analysis
Ali Akbar Fazaeli
Ali Akbar Fazaeli

Associate Professor of Health Economics

Department

School of Public Health

Tehran University of Medical Sciences

Related Documents
1. Is Palbociclib a Cost-Effective Strategy in the Second-Line Treatment of Metastatic Breast Cancer in Iran?, Expert Review of Pharmacoeconomics and Outcomes Research (2023)
All Documents
1. Agenda Setting for Health Equity Assessment Through the Lenses of Social Determinants of Health Using Machine Learning Approach: A Framework and Preliminary Pilot Study, BioData Mining (2025)
2. Analysis of National Health Accounts in Iran (2002–2020), Payesh (2025)
3. Applications of Artificial Intelligence and the Challenges in Health Technology Assessment: A Scoping Review and Framework With a Focus on Economic Dimensions, Health Economics Review (2025)
4. Strategies for Managing Nurse Migration From Iran: A Qualitative Study; راهکارهای مدیریت مهاجرت پرستاران از ایران: یک مطالعه کیفی, Iran Occupational Health (2025)
5. The Effect of the Covid-19 Pandemic on Medicinal Plants Consumption Among Iranian Households: Determinants and Consumption Patterns, Medical Journal of the Islamic Republic of Iran (2025)
6. Volume-Cost Relationship in Pancreatic Surgery: A Scoping Review, Health Policy and Technology (2025)
7. Exploring the Driving Forces and Scenario Analysis for Catastrophic and Impoverishing Health Expenditures in Iran, BMC Health Services Research (2024)
8. Non-Covid-19 Hospitalization and Mortality During the Covid-19 Pandemic in Iran: A Longitudinal Assessment of 41 Million People in 2019–2022, BMC Public Health (2024)
9. Nurse Migration Management Strategies: A Scoping Review; راهکارهای مدیریت مهاجرت پرستاران: یک مرور حیطهای, Journal of Health Administration (2024)
10. Prevalence and Determinants of Catastrophic Healthcare Expenditures in Iran From 2013 to 2019, Journal of Preventive Medicine and Public Health (2024)
11. Robust Prediction of Healthcare Inflation Rate With Statistical and Ai Methods in Iran, Journal of Applied Mathematics (2024)
12. Cost-Utility Analysis of Palbociclib + Letrozole and Ribociclib + Letrozole Versus Letrozole Monotherapy in the First-Line Treatment of Metastatic Breast Cancer in Iran Using Partitioned Survival Model, Health Economics Review (2023)
13. Determinants of Catastrophic Health Expenditures: A Study in Hamedan, Iran, Journal of Health Sciences and Surveillance System (2023)
14. Is Palbociclib a Cost-Effective Strategy in the Second-Line Treatment of Metastatic Breast Cancer in Iran?, Expert Review of Pharmacoeconomics and Outcomes Research (2023)
15. Policy Analysis of the Protection of Iranian Households Against Catastrophic Health Expenditures: A Qualitative Analysis, BMC Health Services Research (2023)
16. The Application of Artificial Intelligence in Health Financing: A Scoping Review, Cost Effectiveness and Resource Allocation (2023)
17. The Variations in Catastrophic and Impoverishing Health Expenditures, and Its Determinants in Iran: A Scoping Review, Medical Journal of the Islamic Republic of Iran (2023)
18. Factors Associated With the Salt Intake Behaviors in Women in a High-Salt Intake Setting, Nutrition and Food Science (2022)
19. Future Financing Scenarios for Iran's Healthcare System, Archives of Iranian Medicine (2022)
20. Hospital Efficiency Measurement in the West of Iran: Data Envelopment Analysis and Econometric Approach, Cost Effectiveness and Resource Allocation (2022)
21. Author Correction: Mapping Local Patterns of Childhood Overweight and Wasting in Low- and Middle-Income Countries Between 2000 and 2017 (Nature Medicine, (2020), 26, 5, (750-759), 10.1038/S41591-020-0807-6), Nature Medicine (2020)
22. Author Correction: Mapping Local Patterns of Childhood Overweight and Wasting in Low- and Middle-Income Countries Between 2000 and 2017 (Nature Medicine, (2020), 26, 5, (750-759), 10.1038/S41591-020-0807-6), Nature Medicine (2020)
23. Department of Error: Mapping Geographical Inequalities in Childhood Diarrhoeal Morbidity and Mortality in Low-Income and Middle-Income Countries, 2000–17: Analysis for the Global Burden of Disease Study 2017 (The Lancet (2020) 395(10239) (1779–1801), (S0140673620301148), (10.1016/S0140-6736(20)30114-8)), The Lancet (2020)
24. Department of Error: Mapping Geographical Inequalities in Childhood Diarrhoeal Morbidity and Mortality in Low-Income and Middle-Income Countries, 2000–17: Analysis for the Global Burden of Disease Study 2017 (The Lancet (2020) 395(10239) (1779–1801), (S0140673620301148), (10.1016/S0140-6736(20)30114-8)), The Lancet (2020)
25. Developing and Testing an Instrument to Measure the Factors Affecting the Salt Restriction Behaviors Among Women, Journal of Research in Health Sciences (2020)
26. Five Insights From the Global Burden of Disease Study 2019, The Lancet (2020)
27. Five Insights From the Global Burden of Disease Study 2019, The Lancet (2020)
28. Global Age-Sex-Specific Fertility, Mortality, Healthy Life Expectancy (Hale), and Population Estimates in 204 Countries and Territories, 1950–2019: A Comprehensive Demographic Analysis for the Global Burden of Disease Study 2019, The Lancet (2020)
29. Global Age-Sex-Specific Fertility, Mortality, Healthy Life Expectancy (Hale), and Population Estimates in 204 Countries and Territories, 1950–2019: A Comprehensive Demographic Analysis for the Global Burden of Disease Study 2019, The Lancet (2020)
30. Global Burden of 369 Diseases and Injuries in 204 Countries and Territories, 1990–2019: A Systematic Analysis for the Global Burden of Disease Study 2019, The Lancet (2020)
31. Global Burden of 369 Diseases and Injuries in 204 Countries and Territories, 1990–2019: A Systematic Analysis for the Global Burden of Disease Study 2019, The Lancet (2020)
32. Mapping Geographical Inequalities in Childhood Diarrhoeal Morbidity and Mortality in Low-Income and Middle-Income Countries, 2000-17: Analysis for the Global Burden of Disease Study 2017, The Lancet (2020)
33. Mapping Geographical Inequalities in Childhood Diarrhoeal Morbidity and Mortality in Low-Income and Middle-Income Countries, 2000-17: Analysis for the Global Burden of Disease Study 2017, The Lancet (2020)
34. Mapping Local Patterns of Childhood Overweight and Wasting in Low- and Middle-Income Countries Between 2000 and 2017, Nature Medicine (2020)
35. Mapping Local Patterns of Childhood Overweight and Wasting in Low- and Middle-Income Countries Between 2000 and 2017, Nature Medicine (2020)
36. Technical Efficiency in Health Production: A Comparison Between Iran and Other Upper Middle-Income Countries, Health Policy and Technology (2020)
37. Erratum: Global, Regional, and National Comparative Risk Assessment of 84 Behavioural, Environmental and Occupational, and Metabolic Risks or Clusters of Risks for 195 Countries and Territories, 1990–2017: A Systematic Analysis for the Global Burden of Disease Study 2017 (The Lancet (2018) 392(10159) (1923–1994), (S0140673618322256), (10.1016/S0140-6736(18)32225-6)), The Lancet (2019)
38. Erratum: Global, Regional, and National Comparative Risk Assessment of 84 Behavioural, Environmental and Occupational, and Metabolic Risks or Clusters of Risks for 195 Countries and Territories, 1990–2017: A Systematic Analysis for the Global Burden of Disease Study 2017 (The Lancet (2018) 392(10159) (1923–1994), (S0140673618322256), (10.1016/S0140-6736(18)32225-6)), The Lancet (2019)
39. Mapping 123 Million Neonatal, Infant and Child Deaths Between 2000 and 2017, Nature (2019)
40. Mapping 123 Million Neonatal, Infant and Child Deaths Between 2000 and 2017, Nature (2019)
41. Past, Present, and Future of Global Health Financing: A Review of Development Assistance, Government, Out-Of-Pocket, and Other Private Spending on Health for 195 Countries, 1995-2050, The Lancet (2019)
42. Global, Regional, and National Comparative Risk Assessment of 84 Behavioural, Environmental and Occupational, and Metabolic Risks or Clusters of Risks for 195 Countries and Territories, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017, The Lancet (2018)
43. Global, Regional, and National Comparative Risk Assessment of 84 Behavioural, Environmental and Occupational, and Metabolic Risks or Clusters of Risks for 195 Countries and Territories, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017, The Lancet (2018)
44. Global, Regional, and National Disability-Adjusted Life-Years (Dalys) for 359 Diseases and Injuries and Healthy Life Expectancy (Hale) for 195 Countries and Territories, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017, The Lancet (2018)
45. Global, Regional, and National Disability-Adjusted Life-Years (Dalys) for 359 Diseases and Injuries and Healthy Life Expectancy (Hale) for 195 Countries and Territories, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017, The Lancet (2018)
46. Measuring Progress From 1990 to 2017 and Projecting Attainment to 2030 of the Health-Related Sustainable Development Goals for 195 Countries and Territories: A Systematic Analysis for the Global Burden of Disease Study 2017, The Lancet (2018)
47. Measuring Progress From 1990 to 2017 and Projecting Attainment to 2030 of the Health-Related Sustainable Development Goals for 195 Countries and Territories: A Systematic Analysis for the Global Burden of Disease Study 2017, The Lancet (2018)